FY 2019 Labor/HHS appropriations bill as it relates to funding for newborn screening.
Education about the RUSP (Recommended Uniform Screening Panel) as it relates to SMA.
Duration: July 1, 2010
to
December 31, 2018
General Issues: Health Issues , Medicare/Medicaid , Budget/Appropriations , Copyright/Patent/Trademark , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code
Spending: about $1,700,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2010: House of Representatives, U.S. Senate, Health & Human Services - Dept of (HHS), House of Representatives,, U.S. Senate,
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Darren Willcox Asst for Policy, Speaker Dennis Hastert
Admin Asst; Leg Dir; Leg Asst, Cong. Porter Goss
House Rules Comm Assoc, Subcomm Staff Dir.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2018
W Strategies, LLC terminated an engagement in which they represented Biogen on Jan. 22, 2019.
Original Filing: 301015919.xml
Lobbying Issues
FY 2019 Labor/HHS appropriations bill as it relates to funding for newborn screening.
Education about the RUSP (Recommended Uniform Screening Panel) as it relates to SMA.
3rd Quarter, 2018
In Q3, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on Oct. 16, 2018.
Original Filing: 300985888.xml
Lobbying Issues
FY 2019 Labor/HHS appropriations bill as it relates to funding for newborn screening.
Education about the RUSP (Recommended Uniform Screening Panel) as it relates to SMA.
Education about innovative contracting and value based payments.
Education about Alzheimer's Disease and implications for the health care system.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D "donut hole" provision.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2018
In Q2, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on July 20, 2018.
Original Filing: 300975507.xml
Lobbying Issues
FY 2019 Labor/HHS appropriations bills as it relates to funding for newborn screening.
Education about the RUSP (Recommended Uniform Screening Panel) as it relates to SMA.
Education about innovative contracting and value based payments.
Education about Alzheimer's Disease and implications for the health care system.
Trump Administration Rx Pricing Blueprint.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about obstacles to patient access for coverage of rare disease therapies in Medicaid.
H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D "donut hole" provision.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
In Q1, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on April 19, 2018.
Original Filing: 300950273.xml
Lobbying Issues
FY 2017/2018 Labor/HHS appropriations bills as it relates to funding for newborn screening.
Education about the RUSP (Recommended Uniform Screening Panel) as it relates to SMA.
Education about innovative contracting and value based payments.
Education about Alzheimer's Disease and implications for the health care system.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about obstacles to patient access for coverage of rare disease therapies in Medicaid.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2017
In Q4, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on Jan. 19, 2018.
Original Filing: 300929336.xml
Lobbying Issues
Education about the value of innovative new medicines.
FY 2017/2018 Labor/HHS appropriations bills as it relates to funding for newborn screening.
Education about innovative contracting and value based payments.
Education about Alzheimer's Disease and implications for the health care system.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about obstacles to patient access for coverage of rare disease therapies in Medicaid.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2017
In Q3, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on Oct. 20, 2017.
Original Filing: 300915531.xml
Lobbying Issues
Education about the value of innovative new medicines.
H.R.1231/S.456: RACE for Children Act.
FY 2017/2018 Labor/HHS appropriations bills as it relates to funding for newborn screening.
H.R.1628: American Health Care Act and Better Care Reconciliation Act.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
Education about Alzheimer's Disease and implications for the health care system.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2017
In Q2, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on July 20, 2017.
Original Filing: 300897242.xml
Lobbying Issues
Education about the value of innovative new medicines.
H.R.1231/S.456: RACE for Children Act.
FY 2017/2018 Labor/HHS appropriations bills as it relates to funding for newborn screening.
H.R. 1628: American Health Care Act.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
Education about Alzheimer's Disease and implications for the health care system.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2017
In Q1, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on April 21, 2017.
Original Filing: 300878594.xml
Lobbying Issues
Education about the value of innovative new medicines.
FY 2017/2018 Labor/HHS appropriations bills as it relates to funding for newborn screening.
H.R. 1628: American Health Care Act.
Education about Alzheimer's Disease and implications for the health care system.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2016
In Q4, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848350.xml
Lobbying Issues
Education about the value of innovative new medicines.
FY 2017 Labor/HHS appropriations bill as it relates to funding for newborn screening.
H.R. 34: 21st Century Cures Conference Report, as it relates to S. 1878: Advancing Hope Act of 2016.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
March 2016 CMS proposed rule implementing a new Part B drug payment model.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2016
In Q3, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300835004.xml
Lobbying Issues
Education about the value of innovative new medicines.
FY 2017 Labor/HHS appropriations bill as it relates to funding for newborn screening.
H.R. 6: 21st Century Cures Act.
S. 1878: Advancing Hope Act of 2016.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
March 2016 CMS proposed rule implementing a new Part B drug payment model.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2016
In Q2, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on July 19, 2016.
Original Filing: 300815116.xml
Lobbying Issues
Education about the value of innovative new medicines.
FY 2017 Labor/HHS appropriations bill as it relates to funding for newborn screening.
H.R. 6: 21st Century Cures Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
March 2016 CMS proposed rule implementing a new Part B drug payment model.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2016
In Q1, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on April 20, 2016.
Original Filing: 300803042.xml
Lobbying Issues
Education about the value of innovative new medicines.
H.R. 6: 21st Century Cures Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
March 2016 CMS proposed rule implementing a new Part B drug payment model.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2015
In Q4, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on Jan. 19, 2016.
Original Filing: 300776302.xml
Lobbying Issues
Education about the value of innovative new medicines.
H.R. 6: 21st Century Cures Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
P.L. 114-74: Bipartisan Budget Act of 2015.
P.L. 114-113: "Consolidated Appropriations Act" with respect to the Protecting Americans from Tax Hikes Act and James Zadroga 9/11 Health and Compensation Reauthorization as it relates to potential offsets.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2015
In Q3, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on Oct. 20, 2015.
Original Filing: 300763585.xml
Lobbying Issues
Education about the value of innovative new medicines.
H.R. 6: 21st Century Cures Act.
Legislative efforts in Senate HELP Committee to promote medical innovation for patients.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 9: Innovation Act, including proposed changes to the Inter Partes Review process at the Patent and Trademark Office (PTO).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, W Strategies, LLC lobbied for Biogen , earning $50,000. The report was filed on July 20, 2015.
Original Filing: 300743450.xml
Lobbying Issues
Education about the value of innovative new medicines.
H.R. 6: 21st Century Cures Act.
Legislative efforts in Senate HELP Committee to promote medical innovation for patients.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 9: Innovation Act, including provisions to reform the Inter Partes Review process at the Patent and Trademark Office (PTO).
S. 632: Strong Patents Act.
S. 1137: PATENT Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2015
In Q1, W Strategies, LLC lobbied for Biogen (Formerly Known As Biogen Idec) , earning $50,000. The report was filed on April 17, 2015.
Original Filing: 300718814.xml
Lobbying Issues
Education about the value of innovative new medicines.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 2: Medicare Access and CHIP Reauthorization Act of 2015.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2014
In Q4, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Jan. 19, 2015.
Original Filing: 300700307.xml
Lobbying Issues
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
H.R. 1281: Newborn Screening Saves Lives Reauthorization Act of 2013.
Education about the value of innovative new medicines.Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Oct. 16, 2014.
Original Filing: 300684689.xml
Lobbying Issues
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
H.R. 1281: Newborn Screening Saves Lives Reauthorization Act of 2013.
H.R. 3303: SOFTWARE Act of 2013.
Education about the value of innovative new medicines.Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on July 14, 2014.
Original Filing: 300664618.xml
Lobbying Issues
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
H.R. 1281: Newborn Screening Saves Lives Reauthorization Act of 2013.
H.R. 3303: SOFTWARE Act of 2013.
Education about the value of innovative new medicines.Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1720: Patent Transparency and Improvements Act.
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2014
In Q1, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on April 14, 2014.
Original Filing: 300635672.xml
Lobbying Issues
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
H.R. 1281: Newborn Screening Saves Lives Reauthorization Act of 2013.
H.R. 3303: SOFTWARE Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4302: Protecting Access to Medicare Act of 2014.
H.R. 4160: Keep the Promise to Seniors Act of 2014.
CMS proposed rule affecting the Medicare Advantage and Medicare Prescription Drug Benefit (Part D) Programs, specifically as it relates to changes to the Part D programs, including coverage of therapeutic classes and non interference.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1720: Patent Transparency and Improvements Act.
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2013
In Q4, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Jan. 14, 2014.
Original Filing: 300621911.xml
Lobbying Issues
Monitored implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
H.R. 1281: Newborn Screening Saves Lives Reauthorization Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2810, S: Medicare Patient Access and Quality Improvement Act of 2013.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Oct. 16, 2013.
Original Filing: 300601802.xml
Lobbying Issues
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
S. 957: Drug Supply Chain Security Act.
S. 959: Pharmaceutical Compounding Quality and Accountability Act.
H.R. 3089: Compounding Clarity Act of 2013.H.R. 3024: The Drug Quality and Security Act.
H.R. 1281: Newborn Screening Saves Lives Reauthorization Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored legislative efforts to reform the Sustainable Growth Rate (SGR) formula for physicians in Medicare.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on July 15, 2013.
Original Filing: 300577193.xml
Lobbying Issues
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
S. 957: Drug Supply Chain Security Act.
S. 959: Pharmaceutical Compounding Quality and Accountability Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored legislative efforts to reform the Sustainable Growth Rate (SGR) formula for physicians in Medicare.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on April 16, 2013.
Original Filing: 300553123.xml
Lobbying Issues
Monitoring legislative initiatives around regulation of compounding pharmacies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 8: American Taxpayer Relief Act of 2012 as it relates to sequestration and Medicare, including updates to the Medicare Sustainable Growth rate formula for physicians and related issues.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Jan. 14, 2013.
Original Filing: 300536608.xml
Lobbying Issues
Monitoring legislative initiatives around regulation of compounding pharmacies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 8: American Taxpayer Relief Act of 2012 as it relates to sequestration and Medicare, including updates to the Medicare Sustainable Growth rate formula for physicians and related issues.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Oct. 19, 2012.
Original Filing: 300512463.xml
Lobbying Issues
P.L. 112-144, The Food and Drug Administration Safety and Innovation Act of 2012.
Agencies Lobbied
U.S. House of Representatives,
Lobbying Issues
H.J.Res. 117: Continuing Appropriations Resolution for Fiscal Year 2013.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on July 20, 2012.
Original Filing: 300494045.xml
Lobbying Issues
H.R. 5651: Food and Drug Administration Reform Act of 2012, S. 3187: Food and Drug Administration Safety and Innovation Act of 2012, particularly provisions relating to accelerated approval of drugs.
Advocated for reforms of Risk Evaluation and Mitigation Strategies in FDA bills.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on April 4, 2012.
Original Filing: 300464001.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to a regulatory pathway for biosimilars and opposing efforts in the President's Budget to alter that pathway.
Education about reforming the Risk Evaluation and Mitigation Strategies provision in the FDA in the FDA Administration and Amendments Act of 2007 with respect to the upcoming Prescription Drug User Fee Act Reauthorization for FY 2013-2017.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored H.R. 3630: Temporary Payroll Tax Cut Continuation Act as it relates to Medicare reimbursement for Part B drugs.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Jan. 19, 2012.
Original Filing: 300445569.xml
Lobbying Issues
Education about reforming the Risk Evaluation and Mitigation Strategies provision in the FDA in the FDA Administration and Amendments Act of 2007 with respect to the upcoming Prescription Drug User Fee Act Reauthorization for FY 2013-2017.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3630/3765: Temporary Payroll Tax Cut Continuation Act as they relate to Medicare reimbursement for Part B drugs.
P.L. 112-25 - The Budget Control Act of 2011 as it relates to proposals affecting reimbursement of Part B drugs.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Oct. 19, 2011.
Original Filing: 300423976.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to a regulatory pathway for biosimilars.
Monitored deficit reduction initiatives related to enactment of an increase in the U.S. federal debt ceiling.
P.L. 112-25 - The Budget Control Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Educated staff about maintaining strong Intellectual Property provisions in the TransPacific Partnership Agreement.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2011
In Q2, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on July 19, 2011.
Original Filing: 300395819.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Monitored deficit reduction initiatives related to enactment of an increase in the U.S. federal debt ceiling.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent Reform
H.R. 1249 - America Invents Act of 2011
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2011
In Q1, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on April 13, 2011.
Original Filing: 300369455.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent Reform
S.23 - America Invents Act of 2011
H.R. 1249 - America Invents Act of 2011
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Jan. 12, 2011.
Original Filing: 300346587.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, W Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Oct. 18, 2010.
Original Filing: 300321260.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
W Strategies, LLC filed a lobbying registration on Aug. 9, 2010 to represent Biogen Idec, effective July 1, 2010.
Original Filing: 300306722.xml
Issue(s) they said they’d lobby about: Implementation of PPACA, including provisions related to comparative effectiveness research and a regulatory pathway for biosimilars.
Patent Reform issues.
Tax Extenders issues; American Jobs and Closing Tax Loophoes Act. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...